Advanced Enzyme Technologies has scheduled a Board of Directors meeting for May 09, 2026. The board will review the company’s standalone and consolidated annual financial statements for the fiscal year ended March 31, 2026, alongside the results for the fourth quarter. Furthermore, the meeting will focus on the recommendation of a final dividend for the 2025-26 fiscal year and potentially an interim dividend for the 2026-27 financial year.
Upcoming Board Meeting Agenda
The management of Advanced Enzyme Technologies has announced that a meeting of its Board of Directors is slated for May 09, 2026. The primary objective of this session is the review and approval of the company’s financial performance for both the standalone and consolidated entities for the year ending March 31, 2026. This comprehensive review will also encompass the specific financial outcomes for the fourth quarter of the fiscal year.
Dividend Considerations
A key highlight of the upcoming meeting involves the company’s capital allocation strategy. The Board will deliberate on recommending a final dividend to shareholders for the financial year concluded on March 31, 2026. Additionally, the directors are set to evaluate the possibility of declaring an interim dividend for the ongoing financial year ending March 31, 2027, providing investors with early insight into potential shareholder returns for the new fiscal cycle.
Trading Window Update
In accordance with corporate governance protocols, the company has confirmed that the Trading Window for dealing in its securities remains closed. This restriction, which was initiated on March 26, 2026, will continue to be in effect until May 11, 2026, to ensure confidentiality ahead of the scheduled financial disclosures.
Source: BSE
